MX2007008136A - Metodo para invertir la resistencia multiple en celulas animales. - Google Patents

Metodo para invertir la resistencia multiple en celulas animales.

Info

Publication number
MX2007008136A
MX2007008136A MX2007008136A MX2007008136A MX2007008136A MX 2007008136 A MX2007008136 A MX 2007008136A MX 2007008136 A MX2007008136 A MX 2007008136A MX 2007008136 A MX2007008136 A MX 2007008136A MX 2007008136 A MX2007008136 A MX 2007008136A
Authority
MX
Mexico
Prior art keywords
animal cells
multiple resistance
reversing multiple
reversing
resistance
Prior art date
Application number
MX2007008136A
Other languages
English (en)
Spanish (es)
Inventor
Per Sonne Holm
Original Assignee
Per Sonne Holm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Per Sonne Holm filed Critical Per Sonne Holm
Publication of MX2007008136A publication Critical patent/MX2007008136A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2007008136A 2004-12-31 2006-01-02 Metodo para invertir la resistencia multiple en celulas animales. MX2007008136A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004063639 2004-12-31
US65108505P 2005-02-08 2005-02-08
PCT/EP2006/000009 WO2006070023A2 (en) 2004-12-31 2006-01-02 Method for reversing multiple resistance in animal cells

Publications (1)

Publication Number Publication Date
MX2007008136A true MX2007008136A (es) 2008-02-12

Family

ID=36582063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008136A MX2007008136A (es) 2004-12-31 2006-01-02 Metodo para invertir la resistencia multiple en celulas animales.

Country Status (10)

Country Link
US (4) US20100310554A1 (enExample)
EP (1) EP1831382B1 (enExample)
JP (1) JP5584393B2 (enExample)
KR (1) KR101527213B1 (enExample)
CN (1) CN101128593B (enExample)
AU (1) AU2006203736B2 (enExample)
CA (1) CA2592699C (enExample)
MX (1) MX2007008136A (enExample)
SG (1) SG158133A1 (enExample)
WO (1) WO2006070023A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1655827B (zh) 2002-05-27 2010-06-23 佩尔·松内·霍尔姆 腺病毒和编码其的核酸的新应用
WO2005051430A1 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
EP1830864A2 (de) * 2004-12-31 2007-09-12 Per Sonne Holm E1 -minus adenoviren und deren verwendung
WO2010068794A2 (en) 2008-12-10 2010-06-17 The General Hospital Corporation Hif inhibitors and use thereof
CN107982548A (zh) 2012-02-07 2018-05-04 全球生物疗法有限公司 核酸输送的区室化方法及其组合物和应用
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
EP3033414A4 (en) 2013-08-12 2017-03-22 Invivosciences Inc. Automated cell culture system and method
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
US10813957B2 (en) * 2016-10-07 2020-10-27 Miami University Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EP3610870A4 (en) * 2017-03-31 2020-12-09 Ogata, Hisanobu METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
EP3630959A4 (en) * 2017-05-24 2021-03-17 EpicentRx, Inc. ANTI-ANGIOGENIC ADENOVIRUS
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
CN113774031B (zh) * 2020-06-10 2024-04-02 广州恩宝生物医药科技有限公司 一种复制型人腺病毒及其应用
CN118119703A (zh) * 2021-09-30 2024-05-31 富士胶片株式会社 腺相关病毒的制造方法、细胞及表达载体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3827163B2 (ja) * 1995-03-24 2006-09-27 ジェンザイム・コーポレーション 遺伝子治療用のアデノウイルスベクター
AU2319497A (en) * 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
DK1199368T3 (da) * 1998-07-07 2004-04-13 Transgene Sa Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse
AU2145300A (en) * 1998-11-18 2000-06-05 Canji, Inc. Adenoviral vectors
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
DE19929569A1 (de) * 1999-06-21 2000-12-28 Holm Per Sonne Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
AU6425800A (en) * 1999-06-30 2001-01-22 Max-Delbruck-Centrum Fur Molekulare Medizin Agents for the diagnosis, prognosis and treatment of malignant diseases
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
US6635476B1 (en) * 1999-10-15 2003-10-21 Canji, Inc. Targeted vectors
US7048920B2 (en) * 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US20030095989A1 (en) * 2000-12-18 2003-05-22 Irving John M. Chimeric cytolytic viruses for cancer treatment
AU2002343901A1 (en) * 2001-09-29 2003-04-14 Kim, Joo-Hang Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
DE10150984A1 (de) * 2001-10-16 2003-04-17 Holm Per Sonne Verwendung des adenoviralen E2-late-Promotors
WO2004001032A2 (en) * 2002-04-25 2003-12-31 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
CN1655827B (zh) * 2002-05-27 2010-06-23 佩尔·松内·霍尔姆 腺病毒和编码其的核酸的新应用
JP4988199B2 (ja) * 2002-10-15 2012-08-01 ホルム，ペル・ゾンネ 新規アデノウイルス、それをコードする核酸及びその使用
US8951772B2 (en) * 2002-10-15 2015-02-10 Per Sonne Holm Adenoviruses, nucleic acids coding therefor, and use thereof
CA2522380A1 (en) * 2003-03-19 2004-09-30 Isogenis, Inc. Specific inhibition of allorejection
JP4871726B2 (ja) * 2003-04-28 2012-02-08 ナノシス・インク． 超疎液性表面、その作製法及び用途
WO2005051430A1 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
US20060270016A1 (en) * 2003-11-14 2006-11-30 Holm Per S Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
EP1830864A2 (de) 2004-12-31 2007-09-12 Per Sonne Holm E1 -minus adenoviren und deren verwendung
US20070292396A1 (en) * 2006-03-02 2007-12-20 Juan Fueyo Combination therapy with oncolytic adenovirus

Also Published As

Publication number Publication date
CA2592699C (en) 2023-02-21
SG158133A1 (en) 2010-01-29
CA2592699A1 (en) 2006-07-06
EP1831382A2 (en) 2007-09-12
WO2006070023A3 (en) 2006-09-21
JP5584393B2 (ja) 2014-09-03
KR101527213B1 (ko) 2015-06-09
KR20070103412A (ko) 2007-10-23
CN101128593B (zh) 2014-09-03
CN101128593A (zh) 2008-02-20
WO2006070023A2 (en) 2006-07-06
US20110286999A1 (en) 2011-11-24
US20220339219A1 (en) 2022-10-27
US20100310554A1 (en) 2010-12-09
US20170252443A1 (en) 2017-09-07
AU2006203736A1 (en) 2006-07-06
EP1831382B1 (en) 2023-01-18
JP2008526188A (ja) 2008-07-24
AU2006203736B2 (en) 2012-03-29
US11369650B2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
SG158133A1 (en) Method for reversing multiple resistance in animal cells
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
IL183940A0 (en) Glp-1 agonists, compositions, methods and uses
DE602005010109D1 (de) 1,1a,5,5a-tetrahydro-3-thia-cyclopropaäaüpentaleneptor-agonisten
NO20053161D0 (no) Mikrobedrepende sammensetning.
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EP1912667A4 (en) CONCENTRATED PROTEIN LYOPHILISATES, ASSOCIATED METHODS AND USES THEREOF
DE602004012154D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren
FI20045162A0 (fi) Ryhmäviestintä viestinjärjestelmässä
DE502005007723D1 (de) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone,
ATE556446T1 (de) Batterieanoden
MX2007002917A (es) Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.
NO20054053D0 (no) Triazolforbindelser anvendbare i terapi.
MX2008001638A (es) Metodo de espaciado de piel entumecida.
GB0413142D0 (en) Improvements in, or relating to testing
ITMI20051746A1 (it) Macchina i.s.
BR8203451Y1 (pt) disposição construtiva em copo descartável.
AU2004906102A0 (en) Softshu horseshoe Rev. I
ITFR20040018A1 (it) Antislavina & i.s.m.
UA4341U (uk) Літична суміш для проведення гібернації та гіпотермії
AU300905S (en) Storage unit
AU2005900374A0 (en) The fish hooka, new submission
NL1025973A1 (nl) Hengsel.
AU300898S (en) Storge unit
HU2993U (en) Portable, heat-preserving thermo-bottle

Legal Events

Date Code Title Description
FG Grant or registration